Biochemical Engineering Special Interest Group
biological engineering professionals
12 July 2016

Cell Medica buys Delenex for tech to power next-gen CAR collaboration with Baylor

Cell Medica has bought Delenex, a Swiss biotech that spun out of ESBATech as part of its $589 million (€531 million) takeover by Novartis’ ($NVS) Alcon. The deal gives Cell Medica single-chain variable fragment (scFv) technology that will serve as the targeting system for the chimeric antigen receptor (CAR) therapies it is codeveloping with Baylor College of Medicine. London-based Cell Medica has paid an undisclosed fee to gain access to the scFv technology. Source: FierceBiotech 12/7/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).